Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26458

Title: Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Authors: Van Praet, Charles
Rottey, Sylvie
Van Hende, Fransien
Pelgrims, Gino
Demey, Wim
Van Aelst, Filip
Wynendaele, Wim
Gil, Thierry
Schatteman, Peter
Filleul, Bertrand
Schallier, Denis
Machiels, Jean-Pascal
Schrijvers, Dirk
Everaert, Els
D'Hondt, Lionel
Werbrouck, Patrick
Vermeij, Joanna
Mebis, Jeroen
Clausse, Marylene
Rasschaert, Marika
Van Erps, Joanna
Verheezen, Jolanda
Van Haverbeke, Jan
Goeminne, Jean-Charles
Lumen, Nicolaas
Issue Date: 2017
Citation: CLINICAL GENITOURINARY CANCER, 15(4), p. 502-508
Abstract: Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/dL, > 10 metastases, ECOG performance status >= 2, radiographic progression, and time since diagnosis < 90 months. A prognostic model stratifies patients into 3 groups with different estimated survival, which can aid in patient counseling.Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. Materials and Methods: This is a retrospective multicentric analysis of 368 patients with mCRPC starting AA with prednisone after docetaxel. Cox proportional hazards statistics were applied. A multivariate model was constructed based on significant univariate predictors by using a manual stepwise forward and backward selection strategy. Model performance was determined by using receiver operating characteristic (ROC) curves. Results: Univariate analysis identified 20 significant OS predictors. A multivariate model was constructed, based on 220 patients, incorporating 5 independent risk factors for decreased OS at the time of AA initiation: hemoglobin <12 g/dL (hazard ratio [HR] 2.02), > 10 metastases (HR 1.80), ECOG performance status >= 2 (HR 1.88), radiographic progression (HR 1.50), and time since diagnosis < 90 months (HR 1.66, all P <.05). Patients were stratified into 3 groups: good (0-2 risk factors, median OS 22.6 months), intermediate (3 risk factors, median OS 13.9 months), and poor prognosis (4-5 risk factors, median OS 6.2 months). The area under the ROC curve based on the event "death by the time of median OS (13.3 months)" was 0.736 (95% confidence interval 0.670-0.803). Conclusion: We identified 5 readily available risk factors independently associated with decreased OS. The resulting model may be used for patient counseling in daily clinical practice, as well as patient stratification in clinical trials. (C) 2017 Elsevier Inc. All rights reserved.
URI: http://hdl.handle.net/1942/26458
DOI: 10.1016/j.clgc.2017.01.019
ISI #: 000407736900041
ISSN: 1558-7673
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version313.98 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.